Conceptio › Archive › ClinicalTrials.gov
ClinicalTrials.govpublic full text

A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)

Regeneron Pharmaceuticals · 2026
ClinicalTrials.gov · Datasets · License: Public Domain · 2026
Open Source ↗
hr
high risk smoldering multiple myeloma (hr-smm), linvoseltamab, multiple myeloma (mm), b cell maturation antigen (bcma), bispecific antibody, smoldering multiple myeloma (smm), smoldering myeloma, hr-smm, linozyfic, darzalex, interventional, phase3
This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Related documents

Record · ID 913344
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.